SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

Core Viewpoint - A securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. on behalf of investors who purchased or acquired its securities between June 16, 2025, and January 8, 2026, alleging violations of the Securities Exchange Act of 1934 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey, claiming that the company and certain senior officers made misrepresentations regarding the New Drug Application for Anaphylm (Dibutepinephrine) sublingual film [5][6]. - Investors are encouraged to join the class action and can contact the Investor Relations Manager for more information [3][9]. Group 2: Participation Information - Individuals wishing to serve as lead plaintiff must file papers by May 4, 2026, and participation does not require serving as lead plaintiff to share in any recovery [4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [7].